Inpatient Use of Personal Continuous Glucose Monitor (CGM) to Improve Diabetes Mellitus Control
ConditionDiabetes Mellitus
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this research is to prove that data generated by your real-time personal continuous glucose monitors CGMs brought in the hospital at the time of hospitalization can be monitored and safely used to guide insulin therapy aiming to improve glycemic control and to diminish the hypoglycemia and hyperglycemia episodes without negatively affecting patients' satisfaction, providers and your nurses satisfaction with how glucose is monitored and treated in the hospital.
Eligibility criteria
Qualifiers
Patients with ages above 18 years old at the time of informed consent.
Male or female
Admitted to non-ICU setting in brick-and-mortar medical and surgical ward or admitted to Advanced Care at Home Program.
Admitted under observation or inpatient status.
Disqualifiers
Participants unable to provide informed medical consent.
Participants admitted to Intensive Care Units (ICU). Enrollment is possible after transferring out of the ICU.
Actively being treated for DKA (diabetes ketoacidosis) or HHS (hyperosmolar hyperglycemic state)
Patients with a diagnosis of liver cirrhosis.
Trial design
Treatments tested in this trial
- Real time CGM data monitoring
- Insulin dose adjustment based on glucometer and CGM glucose data trends
- Share CGM data on admission and on discharge from the hospital
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov